Mixed Phenotype Acute Leukemia Clinical Trials in Houston, Texas

7 studies are recruiting for mixed phenotype acute leukemia in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

   Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 4 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, …

   Stage

   Phase 1

   Ages

   0 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   57 in total

   Run by

   Syndax Pharmaceuticals

   See if you can join NCT04065399 on ClinicalTrials.gov

2. Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

   This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab ozogamicin is a monoclonal antibody, which is a type of prote…

   Stage

   Phase 3

   Ages

   1 to 25

   Site

   Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas

   Locations

   231 in total

   Run by

   Children's Oncology Group

   See if you can join NCT03959085 on ClinicalTrials.gov

3. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

   This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide informat…

   Stage

   Phase 1

   Ages

   Up to 22

   Site

   Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas

   Locations

   184 in total

   Run by

   PedAL BCU, LLC

   See if you can join NCT04726241 on ClinicalTrials.gov

4. Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

   This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.

   Stage

   Phase 1

   Ages

   13 to 90

   Site

   University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   11 in total

   Run by

   Vironexis Biotherapeutics Inc.

   See if you can join NCT06533579 on ClinicalTrials.gov

5. A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

   This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic malignancies.

   Stage

   Phase 1

   Ages

   12 to 78

   Site

   University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   12 in total

   Run by

   Orca Biosystems, Inc.

   See if you can join NCT03802695 on ClinicalTrials.gov

6. A Study of Revumenib and Mezigdomide in People With Leukemia

   The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-r, NUP98-r, and NPM1-m acute leukemias.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   MD Anderson Cancer Center (Data Collection Only), Houston, Texas

   Locations

   10 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07356154 on ClinicalTrials.gov

7. Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

   Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patie…

   Stage

   Phase 1

   Ages

   1 to 21

   Site

   Texas Children's Hospital/Baylor College of Medicine, Houston, Texas

   Locations

   31 in total

   Run by

   Therapeutic Advances in Childhood Leukemia Consortium

   See if you can join NCT05476770 on ClinicalTrials.gov